Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy
- PMID: 33125888
- DOI: 10.1016/j.cell.2020.10.011
Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy
Abstract
Targeting cancer neoantigens generated by tumor-exclusive somatic mutations is an attractive yet challenging strategy for the robust and specific elimination of tumor cells by cellular immunotherapy. In this issue of Cell, Wells et al. describe a consortium-based approach to optimize bioinformatics pipelines to sensitively and accurately predict immunogenic neoantigens from next-generation sequencing data.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests R.J.K., R.C.L., and N.P.R. are employed by and own equity in Lyell Immunopharma.
Comment on
-
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.Cell. 2020 Oct 29;183(3):818-834.e13. doi: 10.1016/j.cell.2020.09.015. Epub 2020 Oct 9. Cell. 2020. PMID: 33038342 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
